Table 1 New treatments in HHT, case reports and case series
From: Future treatments for hereditary hemorrhagic telangiectasia
Ref. | Treatment | n (HHT Type) | Sex/ Age | Symptoms | Treatment indication | Treatment | Efficacy of treatment |
|---|---|---|---|---|---|---|---|
[44] | Tacrolimus | 1 (HHT2) | M 51 | Epistaxis GI bleeding | Epistaxis | Dose unknown | ↓ Epistaxis |
[45] | Pazopanib | 1 (HHT2) | M 61 | Epistaxis Anemia | Epistaxis | 50 mg/d during 1 month then: 100 mg/d | ↓Epistaxis |
[46] | Pazopanib | 7 (3 HHT1, 3 HHT2, 1 JP/HHT) | Anemia Epistaxis | Anemia, OR, severe epistaxis with iron deficiency | 50 mg /d during 12 weeks | ↓epistaxis duration ↗ Hb ↗ SF-36 | |
[47] | Nintedanib | 1 (HHT2) | M 70 | Epistaxis Telangiectasias | Pulmonary fibrosis | 300 mg/d | ↓Epistaxis and telangiectasias |
[48] | Sunitinib | 1 (?) | M 68 | Epistaxis Multiple metastases | Oncology | 37.5 mg/d | ↓ epistaxis frequency and intensity ↓facial telangiectasia |
[49] | Buparlisib | 1 (HHT2) | F 49 | Epistaxis | Oncology | 100 mg/d | ↓ frequency of epistaxis |